OmniAb, Inc. (OABI)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, OmniAb, Inc. currently loses $44.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 30
in 5 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
OmniAb’s earnings topped consensus as adjusted EPS of -$0.05 beat the -$0.12 estimate by $0.07, alongside revenue that surged 244.2% year over year to about $13.4 million in the second fiscal quarter of 2026, reported August 6, 2026, up from roughly $3.9 million a year ago as its antibody-discovery platform work (including OmniRat, OmniChicken, and OmniMouse) generated higher partner-related activity. Profitability remained negative, with operating income of around -$6.6 million translating to an operating margin of -49.5%, while net income narrowed 63.1% to roughly -$5.9 million versus about -$15.9 million a year earlier. The quarter produced about $2.7 million of operating cash flow. Next-period consensus calls for EPS of -$0.12 on revenue of $3.5 million.
Next report — what to expect
OmniAb, Inc. (OABI) reports next on November 3, 2026. Wall Street expects EPS of -$0.12 on revenue of $3.4 million. For trailing context, revenue rose +244.2% year over year last quarter. The company has beaten EPS in 3 of its 8 most recent quarters, setting a mixed history into this print.
About OmniAb, Inc.
OmniAb, Inc. is a NASDAQ-listed biotechnology company focused on therapeutic antibody discovery through engineered-animal platforms and screening tools that help partners generate human-sequence antibodies and related candidates for human therapeutics. In FY2025, it recorded $18.7 million in revenue through this platform-based discovery business.
Today's Snapshot
The day ended with OABI 2.5% lower at 4.66, in line with a weaker sector. OmniAb said China’s drug regulator approved batoclimab, an immune-disease treatment, through its partners. OABI is due to report earnings on 30 October.
Trading Volume
Below 10d avg (1.3M)
1.2M
vs S&P 500 Today
Underperforming Market
-1.99%
Updated: October 23, 2026 at 20:13 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$2.98 - $4.75Buy
- RSI (14)50.61Neutral
- Stochastic %K (14, 3, 3)62.27Neutral
- MACD Level (12, 26)0.09Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.